Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling.

Bottino DC, Patel M, Kadakia E, Zhou J, Patel C, Neuwirth R, Iartchouk N, Brake R, Venkatakrishnan K, Chakravarty A.

Clin Cancer Res. 2019 Jul 18. doi: 10.1158/1078-0432.CCR-18-3882. [Epub ahead of print]

PMID:
31320596
2.

Stereotactic radiosurgery for ablation of ventricular tachycardia.

Neuwirth R, Cvek J, Knybel L, Jiravsky O, Molenda L, Kodaj M, Fiala M, Peichl P, Feltl D, Januška J, Hecko J, Kautzner J.

Europace. 2019 Jul 1;21(7):1088-1095. doi: 10.1093/europace/euz133.

PMID:
31121018
3.

Stereotactic radiosurgery as a treatment for recurrent ventricular tachycardia associated with cardiac fibroma.

Haskova J, Peichl P, Pirk J, Cvek J, Neuwirth R, Kautzner J.

HeartRhythm Case Rep. 2018 Oct 24;5(1):44-47. doi: 10.1016/j.hrcr.2018.10.007. eCollection 2019 Jan. No abstract available.

4.

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR.

ESMO Open. 2018 Feb 1;3(2):e000291. doi: 10.1136/esmoopen-2017-000291. eCollection 2018.

5.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
6.

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

Burris HA 3rd, Kurkjian CD, Hart L, Pant S, Murphy PB, Jones SF, Neuwirth R, Patel CG, Zohren F, Infante JR.

Cancer Chemother Pharmacol. 2017 Aug;80(2):261-273. doi: 10.1007/s00280-017-3343-4. Epub 2017 Jun 10.

PMID:
28601972
7.

Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.

Kumar SK, Laubach JP, Giove TJ, Quick M, Neuwirth R, Yung G, Rajkumar SV, Richardson PG.

Br J Haematol. 2017 Sep;178(5):756-763. doi: 10.1111/bjh.14754. Epub 2017 Jun 7.

PMID:
28591409
8.

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.

Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K.

J Clin Pharmacol. 2017 Sep;57(9):1183-1193. doi: 10.1002/jcph.906. Epub 2017 Apr 18.

9.

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.

Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S, Neuwirth R, Bózon V.

Invest New Drugs. 2017 Feb;35(1):47-58. doi: 10.1007/s10637-016-0391-2. Epub 2016 Sep 21.

10.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F.

Clin Cancer Res. 2016 Aug 15;22(16):4206-4214. doi: 10.1158/1078-0432.CCR-15-2793. Epub 2016 Mar 22.

11.

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL.

Am J Hematol. 2016 Jun;91(4):400-5. doi: 10.1002/ajh.24300.

12.

Law as a Social Medicine: Enhancing International Inter-regime Regulatory Coopetition as a Means for the Establishment of a Global Health Governance Framework.

Neuwirth RJ, Svetlicinii A.

J Leg Med. 2015 Jul-Dec;36(3-4):330-366. doi: 10.1080/01947648.2016.1161570. No abstract available.

PMID:
28256942
13.

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J.

J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8.

PMID:
26056177
14.

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.

Craig M, Hanna WT, Cabanillas F, Chen CS, Esseltine DL, Neuwirth R, O'Connor OA.

Br J Haematol. 2014 Sep;166(6):920-8. doi: 10.1111/bjh.12991. Epub 2014 Jul 9.

PMID:
25039282
15.

Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.

MacLean DB, Matsui H, Suri A, Neuwirth R, Colombel M.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1445-53. doi: 10.1210/jc.2013-4236. Epub 2014 Apr 24.

PMID:
24762108
16.

Spread of virulent group A Streptococcus type emm59 from Montana to Wyoming, USA.

Brown CC, Olsen RJ, Fittipaldi N, Morman ML, Fort PL, Neuwirth R, Majeed M, Woodward WB, Musser JM.

Emerg Infect Dis. 2014 Apr;20(4):679-81. doi: 10.3201/eid2004.130564.

17.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M.

Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11.

18.

Evaluation of a silver nitrate endometrial ablation fluid delivery system as a chemical treatment for menorrhagia.

Neuwirth RS, Singer A.

J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):627-30. doi: 10.1016/j.jmig.2013.04.003. Epub 2013 May 18.

PMID:
23688602
19.

[Outcomes of catheter ablation of atrial fibrillation in patients over 65 years of age].

Fiala M, Skňouřil L, Toman O, Pindor J, Wojnarová D, Bulková V, Chovančík J, Dorda M, Szymeczek H, Neuwirth R, Vavřík D, Krawiec S, Jiravský O, Rybka L, Lábrová R, Januška J, Spinar J.

Vnitr Lek. 2013 Jan;59(1):16-22. Czech.

PMID:
23427998
20.

Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.

Solh M, Fisher RI, Goy A, de Vos S, Bernstein SH, Esseltine DL, Neuwirth R, Morrison VA.

Leuk Lymphoma. 2013 Oct;54(10):2185-9. doi: 10.3109/10428194.2013.772294. Epub 2013 Mar 8.

PMID:
23383602
21.

[A comparison of two methods of long-term external ECG telemonitoring in patients after ablation for atrial fibrillation].

Chovančík J, Bulková V, Fiala M, Gandalovičová J, Královec S, Neuwirth R, Tolaszová H, Jiravský O, Brada J, Januška J.

Vnitr Lek. 2012 Sep;58(9):633-9. Czech.

PMID:
23094807
22.

[Catheter ablation of atrio-ventricular accessory pathways in the era of ablation therapy of complex arrhythmias: a changing perspective for oncoming generation of electrophysiologists].

Fiala M, Chovančík J, Wojnarová D, Szymeczek H, Pindor J, Bulková V, Neuwirth R, Jiravský O, Vavřík D, Krawiec S, Januška J.

Vnitr Lek. 2012 Jun;58(6):434-8. Czech.

PMID:
22913235
23.

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P.

Clin Cancer Res. 2012 May 15;18(10):2954-63. doi: 10.1158/1078-0432.CCR-11-2873. Epub 2012 Mar 6.

24.

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.

Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A.

Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6.

PMID:
22054286
25.

Global bazaar.

Neuwirth R.

Sci Am. 2011 Sep;305(3):56-63. No abstract available.

PMID:
21870444
26.

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.

van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P.

Haematologica. 2011 Nov;96(11):1662-9. doi: 10.3324/haematol.2010.037978. Epub 2011 Jul 26.

27.

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47. doi: 10.1007/s00280-011-1637-5. Epub 2011 Apr 9.

28.

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.

Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H 3rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A.

Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67. doi: 10.1007/s00280-010-1283-3. Epub 2010 Mar 20.

29.

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.

Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, Trepicchio W, Cooper M, Karol M, von Moltke L, Neuwirth R, Egorin M, Chatta G.

Clin Ther. 2009;31 Pt 2:2444-58. doi: 10.1016/j.clinthera.2009.11.012.

PMID:
20110052
30.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

31.

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.

Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.

Br J Haematol. 2009 Nov;147(4):531-4. doi: 10.1111/j.1365-2141.2009.07875.x. Epub 2009 Sep 1.

PMID:
19725827
32.

Results of complex left atrial ablation of long-lasting persistent atrial fibrillation.

Fiala M, Chovancík J, Wojnarová D, Bulková V, Szymeczek H, Nevralová R, Neuwirth R, Jiravský O, Sknouril L, Dorda M, Januska J, Branny M.

J Interv Card Electrophysiol. 2008 Dec;23(3):189-98. doi: 10.1007/s10840-008-9293-3. Epub 2008 Oct 7.

PMID:
18839297
33.

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG.

J Clin Oncol. 2008 Oct 10;26(29):4784-90. doi: 10.1200/JCO.2007.14.9641. Epub 2008 Aug 18.

PMID:
18711175
34.

Termination of long-lasting persistent versus short-lasting persistent and paroxysmal atrial fibrillation by ablation.

Fiala M, Chovancík J, Nevralová R, Neuwirth R, Jiravský O, Januska J, Branny M.

Pacing Clin Electrophysiol. 2008 Aug;31(8):985-97. doi: 10.1111/j.1540-8159.2008.01126.x.

PMID:
18684255
35.

Pulmonary vein isolation using segmental versus electroanatomical circumferential ablation for paroxysmal atrial fibrillation: over 3-year results of a prospective randomized study.

Fiala M, Chovancík J, Nevralová R, Neuwirth R, Jiravský O, Nykl I, Sknouril L, Dorda M, Januska J, Branny M.

J Interv Card Electrophysiol. 2008 Jun;22(1):13-21. doi: 10.1007/s10840-008-9212-7. Epub 2008 Apr 17.

PMID:
18418704
36.

[Recurrent arrhythmias after catheter ablation of originally paroxysmal atrial fibrillation and results of repeat ablation].

Fiala M, Chovancík J, Moravec R, Wojnarová D, Szymeczek H, Neuwirth R, Nevalová R, Jiravský O, Januska J, Sknouril L, Dorda M, Indrák J, Cerný J, Nykl I, Branny M.

Vnitr Lek. 2007 Dec;53(12):1248-54. Czech.

PMID:
18357858
37.

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC.

Leukemia. 2008 Apr;22(4):842-9. doi: 10.1038/sj.leu.2405087. Epub 2008 Jan 17.

PMID:
18200040
38.

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.

Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G.

Am J Hematol. 2007 Sep;82(9):831-3.

39.

Atrial macroreentry tachycardia in patients without obvious structural heart disease or previous cardiac surgical or catheter intervention: characterization of arrhythmogenic substrates, reentry circuits, and results of catheter ablation.

Fiala M, Chovancík J, Neuwirth R, Nevralová R, Jiravský O, Sknouril L, Dorda M, Januska J, Vodzinská A, Cerný J, Nykl I, Branny M.

J Cardiovasc Electrophysiol. 2007 Aug;18(8):824-32. Epub 2007 May 30.

PMID:
17537207
40.

[Catheter ablation of chronic atrial fibrillation using circumferential and complex linear lesions in the left atrium: modes of arrhythmia termination and long-term clinical outcome].

Fiala M, Chovancík J, Neuwirth R, Nevralová R, Jiravský O, Szymeczek H, Wojnarová D, Moravec R, Sknouril L, Dorda M, Januska J, Nykl I, Cerný J, Branny M.

Vnitr Lek. 2007 Mar;53(3):231-41. Czech.

PMID:
17503636
41.

[Long term effectiveness of surgical cryoablation for chronic atrial fibrillation in patients undergoing surgery for severe mitral valve regurgitation].

Neuwirth R, Fiala M, Branny P, Novosad J, Urban M, Jiravský O, Chovancík J, Nevralová R, Branny M.

Vnitr Lek. 2007 Feb;53(2):151-6. Slovak.

PMID:
17419177
42.
43.

[Idiopathic premature ventricular complexes--catheter ablation as a therapeutic alternative].

Chovancík J, Fiala M, Szymeczek H, Neuwirth R, Nevralová R, Nykl I, Branny M.

Vnitr Lek. 2006 Feb;52(2):124-31. Czech.

PMID:
16623274
44.

SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes.

Humpert PM, Neuwirth R, Battista MJ, Voronko O, von Eynatten M, Konrade I, Rudofsky G Jr, Wendt T, Hamann A, Morcos M, Nawroth PP, Bierhaus A.

Diabetes Care. 2005 Apr;28(4):934-6. No abstract available.

PMID:
15793201
45.

The incidence of endometrial cancer after endometrial ablation in a low-risk population.

Neuwirth RS, Loffer FD, Trenhaile T, Levin B.

J Am Assoc Gynecol Laparosc. 2004 Nov;11(4):492-4.

PMID:
15701191
46.

A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency.

Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM.

J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:715-22.

PMID:
12092685
47.

Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.

Warren KE, Patel MC, Aikin AA, Widemann B, Libucha M, Adamson PC, Neuwirth R, Benziger D, O'Toole T, Ford K, Patronas N, Packer RJ, Balis FM.

Cancer Chemother Pharmacol. 2001 Oct;48(4):275-82.

PMID:
11710627
48.

A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency.

Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SF, Neuwirth RB, Ford KM, Saenger P; Genentech, Inc.-Alkermes, Inc. Collaborative Study Group.

J Clin Endocrinol Metab. 2001 Oct;86(10):4700-6.

PMID:
11600528
49.

Cost effective management of heavy uterine bleeding: ablative methods versus hysterectomy.

Neuwirth RS.

Curr Opin Obstet Gynecol. 2001 Aug;13(4):407-10. Review.

PMID:
11452203
50.

Hysteroscopy and gynecology: past, present, and future.

Neuwirth RS.

J Am Assoc Gynecol Laparosc. 2001 May;8(2):193-8. No abstract available.

PMID:
11342723

Supplemental Content

Loading ...
Support Center